Methylation status of the MGMT gene promoter fails to predict the clinical outcome of glioblastoma patients treated with ACNU plus cisplatin

被引：31
|
作者：
Park, Chul-Kee [2 ,6 ]
Park, Sung-Hye [1 ,5 ]
Lee, Se-Hoon [3 ]
Kim, Chae-Yong [2 ]
Kim, Dong-Wan [3 ]
Paek, Sun Ha [2 ,5 ]
Kim, Dong Gyu [2 ]
Heo, Dae Seog [3 ,6 ]
Kim, Il Han [4 ,6 ]
Jung, Hee-Won [2 ]
机构：
[1] Seoul Natl Univ, Coll Med, Dept Pathol, Seoul 110744, South Korea
[2] Seoul Natl Univ, Coll Med, Dept Neurosurg, Seoul 110744, South Korea
[3] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 151, South Korea
[4] Seoul Natl Univ, Coll Med, Dept Radiat Oncol, Seoul 110744, South Korea
[5] Seoul Natl Univ, Coll Med, Neurosci Res Inst, Seoul 110744, South Korea
[6] Seoul Natl Univ Hosp, Canc Res Inst, Seoul 110744, South Korea
来源：
NEUROPATHOLOGY | 2009年 / 29卷 / 04期
关键词：
glioblastoma; O6-methylguanine-DNA-methyltransferase; survival; DNA-REPAIR GENE; O-6-METHYLGUANINE-DNA METHYLTRANSFERASE; PHASE-II; O-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE; IMMUNOHISTOCHEMICAL EXPRESSION; PROGNOSTIC-SIGNIFICANCE; MALIGNANT GLIOMA; MESSENGER-RNA; TEMOZOLOMIDE; HYPERMETHYLATION;
D O I：
10.1111/j.1440-1789.2008.00998.x
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
We analyzed the methylation status of the O6-methylguanine-DNA methyltransferase (MGMT) promoter using a methylation-specific polymerase chain reaction (MSP) in glioblastoma patients treated with 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea (ACNU) plus cisplatin followed by radiation therapy. Forty-eight patients with interpretable MSP results were included in this study. The MGMT promoter was methylated in 26 patients (54.2%, methylated group) and unmethylated in 22 patients (45.8%, unmethylated group). Comparison of clinical outcomes between the two groups revealed that the methylation status of the MGMT gene promoter was not a prognostic factor for overall survival (P = 0.516) or a predictive factor for radiological response to ACNU plus cisplatin treatment (P = 0.529). The most noteworthy explanation for the result is that the synergistic antitumor effects of ACNU and cisplatin resulting from inactivation of MGMT by cisplatin in MGMT active tumors offset the drug resistance.
引用
收藏
页码：443 / 449
页数：7
相关论文
共 50 条
  • [1] MGMT Promoter Methylation Status and Overall Survival in Glioblastoma Patients
    Xia, Daniel
    Lindeman, Neal
    [J]. LABORATORY INVESTIGATION, 2016, 96 : 437A - 437A
  • [2] MGMT Promoter Methylation Status and Overall Survival in Glioblastoma Patients
    Xia, Daniel
    Lindeman, Neal
    [J]. MODERN PATHOLOGY, 2016, 29 : 437A - 437A
  • [3] MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy
    Consolación Melguizo
    Jose Prados
    Beatriz González
    Raul Ortiz
    Angel Concha
    Pablo Juan Alvarez
    Roberto Madeddu
    Gloria Perazzoli
    Jaime Antonio Oliver
    Rodrigo López
    Fernando Rodríguez-Serrano
    Antonia Aránega
    [J]. Journal of Translational Medicine, 10
  • [4] MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy
    Melguizo, Consolacion
    Prados, Jose
    Gonzalez, Beatriz
    Ortiz, Raul
    Concha, Angel
    Juan Alvarez, Pablo
    Madeddu, Roberto
    Perazzoli, Gloria
    Antonio Oliver, Jaime
    Lopez, Rodrigo
    Rodriguez-Serrano, Fernando
    Aranega, Antonia
    [J]. JOURNAL OF TRANSLATIONAL MEDICINE, 2012, 10
  • [5] MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy
    Gonzalez-Astorga, B.
    Luque, R.
    Castellon, V.
    Gonzalez, E.
    Sanchez, C.
    Soberino, J.
    Gonzalez, C.
    Ruiz, J.
    Zurita, M.
    Delgado, J. R.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S794 - S794
  • [6] MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers
    Gutenberg, A.
    Bock, H. C.
    Brueck, W.
    Doerner, L.
    Mehdorn, H. M.
    Roggendorf, W.
    Westphal, M.
    Felsberg, J.
    Reifenberger, G.
    Giese, A.
    [J]. BRITISH JOURNAL OF NEUROSURGERY, 2013, 27 (06) : 772 - 778
  • [7] MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients
    Brandes, Alba A.
    Franceschi, Enrico
    Tosoni, Alicia
    Blatt, Valeria
    Pession, Annalisa
    Tallini, Giovanni
    Bertorelle, Roberta
    Bartolini, Stefania
    Calbucci, Fabio
    Andreoli, Alvaro
    Frezza, Giampiero
    Leonardi, Marco
    Spagnolli, Federica
    Ermani, Mario
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (13) : 2192 - 2197
  • [8] Correlation of MGMT promoter methylation status with gene and protein expression levels in glioblastoma
    Uno, Miyuki
    Oba-Shinjo, Sueli Mieko
    Camargo, Anamaria Aranha
    Moura, Ricardo Pereira
    de Aguiar, Paulo Henrique
    Cabrera, Hector Navarro
    Begnami, Marcos
    Rosemberg, Sergio
    Teixeira, Manoel Jacobsen
    Nagahashi Marie, Suely Kazue
    [J]. CLINICS, 2011, 66 (10) : 1747 - 1755
  • [9] Influence of Intratumor Heterogeneity on the Predictivity of MGMT Gene Promoter Methylation Status in Glioblastoma
    Brigliadori, Giovanni
    Goffredo, Giulia
    Bartolini, Daniela
    Tosatto, Luigino
    Gurrieri, Lorena
    Mercatali, Laura
    Ibrahim, Toni
    [J]. FRONTIERS IN ONCOLOGY, 2020, 10
  • [10] MGMT Gene Promoter Methylation Status as a Potent Prognostic Factor in Glioblastoma Treated with Temozolomide Chemo-irradiation
    Kim, Y.
    Kim, S.
    Kim, J.
    Cho, J.
    Chang, J.
    Kim, D.
    Lee, K.
    Suh, C.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (02): : S275 - S275
12345